Scalper1 News
Genentech, the U.S. biotech arm of Swiss pharma giant Roche (RHHBY), announced Tuesday that its drug candidate ocrelizumab had succeeded in cutting the relapse rate for multiple-sclerosis patients in two late-stage trials. The goal of the studies was to show ocrelizumab is significantly superior to Rebif, a form of interferon sold by Pfizer (PFE). Genentech said it had succeeded in this, and also reduced the lesions in the brain associated with Scalper1 News
Scalper1 News